Suppr超能文献

布茨和胃肠抑制素促胰液素对人胰多肽和胃泌素的刺激作用:体内外研究

Stimulation of human pancreatic polypeptide and gastrin by Boots and GIH secretin: in vitro and in vivo studies.

作者信息

Meryn S, Bauman W A, Panzer S, Straus E

出版信息

Int J Clin Pharmacol Ther Toxicol. 1987 Jan;25(1):1-6.

PMID:3557722
Abstract

We have studied the concentration of various gastrointestinal peptides in a crude porcine secretin (Boots) preparation and pure natural porcine secretin (GIH, Kabi) preparation. Boots secretin was found to contain 140.3 ng secretin, 1.27 ng human pancreatic polypeptide (hPP), 1.03 ng gastrin, 137.4 ng cholecystokinin (CCK), 241 microU insulin, 1.86 ng vasoactive intestinal polypeptide (VIP), 2.22 ng glucagon and 6.60 ng somatostatin (SRIF) per Crick Harper unit Boots secretin. Sephadex gel filtration demonstrated that the immunoreactivity was due to the hormone per se. GIH secretin contained 240 ng secretin per clinical unit (CU) and less than detectable concentrations of hPP, gastrin, CCK, insulin, VIP, glucagon and SRIF. To determine the clinical significance of having contaminating peptides in Boots secretin, we investigated the effect(s) in 4 subjects. Determined in a highly gastrin-specific assay, the mean plasma gastrin response to Boots secretin administration was slightly, but not significantly greater than the GIH secretin response at 1 and 2.5 minutes. However, in some subjects false positive elevations in plasma gastrin immunoreactivity occurred when some commercially available kit gastrin assays were employed. After intravenous injection of Boots secretin, mean plasma hPP levels rose significantly more than after GIH secretin administration. The mean peak plasma insulin level after GIH secretin administration was significantly higher than after Boots secretin. Neither secretin preparation caused a change in plasma glucose, glucagon and SRIF levels. From these results, it is suggested that GIH secretin be used as the preparation of choice in provocative testing for diagnosing gastrinoma or deficiencies of exocrine pancreatic function.

摘要

我们研究了粗制猪促胰液素(Boots公司产品)制剂和纯天然猪促胰液素(GIH公司产品,卡比公司生产)制剂中各种胃肠肽的浓度。发现每克里克·哈珀单位的Boots促胰液素含有140.3纳克促胰液素、1.27纳克人胰多肽(hPP)、1.03纳克胃泌素、137.4纳克胆囊收缩素(CCK)、241微单位胰岛素、1.86纳克血管活性肠肽(VIP)、2.22纳克胰高血糖素和6.60纳克生长抑素(SRIF)。葡聚糖凝胶过滤显示免疫反应性是由激素本身引起的。GIH促胰液素每临床单位(CU)含有240纳克促胰液素,且hPP、胃泌素、CCK、胰岛素、VIP、胰高血糖素和SRIF的浓度低于可检测水平。为了确定Boots促胰液素中含有污染肽的临床意义,我们在4名受试者中进行了研究。在一项高度特异性的胃泌素测定中,给予Boots促胰液素后血浆胃泌素的平均反应在1分钟和2.5分钟时略高于GIH促胰液素的反应,但无显著差异。然而,当使用一些市售试剂盒进行胃泌素测定时,一些受试者的血浆胃泌素免疫反应性出现假阳性升高。静脉注射Boots促胰液素后,血浆hPP平均水平的升高显著高于注射GIH促胰液素后。给予GIH促胰液素后血浆胰岛素的平均峰值水平显著高于给予Boots促胰液素后。两种促胰液素制剂均未引起血浆葡萄糖、胰高血糖素和SRIF水平的变化。从这些结果来看,建议在诊断胃泌素瘤或外分泌胰腺功能缺陷的激发试验中,选用GIH促胰液素作为制剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验